In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Eti Tsicko's Nandauri, far more psychologically complex than its outline indicates - review Nandauri, named after a Georgian word meaning “The one I long for,” is a dark film that offers a female ...

Add articles to your saved list and come back to them any time. Build-to-rent operator Novus, backed by M&G Real Estate, has extended its reach into the residential sector with the purchase of four ...